.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
QuintilesIMS
US Army
Julphar
McKesson
Novartis
Daiichi Sankyo
Fuji
Dow
Colorcon

Generated: November 19, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,022,713

« Back to Dashboard

Which drugs does patent 7,022,713 protect, and when does it expire?


Patent 7,022,713 protects LIVALO and is included in one NDA. There has been one Paragraph IV challenge on Livalo.

This patent has thirteen patent family members in thirteen countries.

Summary for Patent: 7,022,713

Title:Hyperlipemia therapeutic agent
Abstract:The present invention relates to a hyperlipemia therapeutic agent comprising pitavastatins and eicosapentaenoic acid or an ester derivative thereof as effective ingredients.According to the present invention, a type IIb and type IV hyperlipemia therapeutic agent having an excellent effect of lowering the cholesterol and triglyceride in blood is provided.
Inventor(s): Aoki; Taro (Tokorozawa, JP), Yamaguchi; Junji (Higashimurayama, JP), Sasaki; Yusuke (Higashimurayama, JP)
Assignee: KOWA Co., Ltd. (Nagoya, JP) Nissan Chemical Industries, Ltd. (Tokyo, JP)
Application Number:10/780,640
Patent Claim Types:
see list of patent claims
Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Kowa Co
LIVALO
pitavastatin calcium
TABLET;ORAL022363-001Aug 3, 2009ABRXYesNo► Subscribe► Subscribe ADJUNCITVE THERAPY TO DIET TO REDUCE ELEVATED TOTAL CHOLESTEROL, LOW-DENSITY LIPOPROTEIN CHOLESTEROL, APOLIPOPRTEIN B, TRIGLYCERIDES AND TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA
Kowa Co
LIVALO
pitavastatin calcium
TABLET;ORAL022363-002Aug 3, 2009ABRXYesNo► Subscribe► Subscribe ADJUNCITVE THERAPY TO DIET TO REDUCE ELEVATED TOTAL CHOLESTEROL, LOW-DENSITY LIPOPROTEIN CHOLESTEROL, APOLIPOPRTEIN B, TRIGLYCERIDES AND TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA
Kowa Co
LIVALO
pitavastatin calcium
TABLET;ORAL022363-003Aug 3, 2009ABRXYesYes► Subscribe► Subscribe ADJUNCITVE THERAPY TO DIET TO REDUCE ELEVATED TOTAL CHOLESTEROL, LOW-DENSITY LIPOPROTEIN CHOLESTEROL, APOLIPOPRTEIN B, TRIGLYCERIDES AND TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 7,022,713

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,776,881Hyperlipemia therapeutic agent► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,022,713

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Cyprus1110133► Subscribe
Germany602005019856► Subscribe
Denmark1715865► Subscribe
European Patent Office1715865► Subscribe
Spain2342609► Subscribe
Hong Kong1098953► Subscribe
Japan2007523049► Subscribe
Japan5474276► Subscribe
South Korea20060109988► Subscribe
South Korea101376449► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Julphar
Mallinckrodt
Accenture
Merck
UBS
Boehringer Ingelheim
Daiichi Sankyo
Deloitte
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot